Skip to main content
Premium Trial:

Request an Annual Quote

NIPD Genetics Wins $1.5M From Cypriot Foundation to Develop Liquid Biopsy, PGT Assays

NEW YORK – NIPD Genetics of Cyprus has won $1.5 million in funding from the Research & Innovation Foundation, Cyprus to develop a cancer liquid biopsy test and a preimplantation genetic test (PGT).

Specifically, the company plans to develop a circulating tumor DNA (ctDNA) blood test for the detection of lung, colorectal, breast, prostate, and ovarian cancer that can be used for early cancer detection, diagnosis, disease monitoring, mutation detection for targeted therapy, minimal residual disease detection, and treatment resistance detection. The test will use and further develop the firm's proprietary target capture technology as well as its bioinformatics tools.

In addition, NIPD Genetics plans to develop a comprehensive PGT kit with visualization and analysis software for the detection of chromosomal aneuploidies, structural rearrangements, and monogenic disorders. This test will also use the firm's target capture technology and the company plans to develop novel statistical models and customized bioinformatics pipelines.

NIPD Genetics has been offering a cell-free DNA-based noninvasive prenatal test for fetal aneuploidies, called Veracity, since 2015. The company recently added an expanded prenatal genetic screening test and a number of hereditary and somatic cancer panel tests to its menu.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.